BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 28689987)

  • 1. Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy.
    Zhao W; Zheng XL; Jiang ZN; Liao XB; Zhao SP
    Int J Cardiol; 2017 Dec; 248():355-360. PubMed ID: 28689987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece.
    Liberopoulos E; Vlasserou F; Mitrogianni Z; Papageorgantas I; Elisaf M;
    Angiology; 2012 Apr; 63(3):184-93. PubMed ID: 21676964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.
    Jones PH; Nair R; Thakker KM
    J Am Heart Assoc; 2012 Dec; 1(6):e001800. PubMed ID: 23316314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
    Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
    Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care.
    Bestehorn K; Smolka W; Pittrow D; Schulte H; Assmann G
    Curr Med Res Opin; 2010 Dec; 26(12):2833-9. PubMed ID: 21058895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent lipid abnormalities in statin-treated coronary artery disease patients with and without diabetes in China.
    Wei Y; Guo H; The E; Che W; Shen J; Hou L; Zhao S; Ye P; Li G; Wang D; Jie Q; Hu D
    Int J Cardiol; 2015 Mar; 182():469-75. PubMed ID: 25612824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared to that in men.
    Moreno-Arellano S; Delgado-de-Mendoza J; Santi-Cano MJ
    Nutr Metab Cardiovasc Dis; 2018 Aug; 28(8):810-815. PubMed ID: 29754716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent dyslipidemia in statin-treated patients: the focus on comprehensive lipid management survey in Swiss patients.
    Sudano I; Hess L; Noll G; Arnet D
    Swiss Med Wkly; 2011; 141():w13200. PubMed ID: 21574067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
    Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
    Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
    Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.